What the FDA labels say about taking them together
Fluoxetine and insulin glargine
Insulin glargine's FDA label of June 16, 2026 names fluoxetine in its drug interactions section; fluoxetine's label does not name insulin glargine itself but warns about its class (insulin analogs). The insulin glargine label: “Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline …”
Check it at the source: the fluoxetine FDA label on DailyMed (effective January 8, 2026, Dista Products Company); the insulin glargine FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company).
What does the fluoxetine label say about insulin glargine?
Fluoxetine's label does not name insulin glargine itself; it warns about its class (insulin analogs):
Fluoxetine label, warnings and precautionsAs is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued.
Source: FDA drug label (Prozac), NDA018936 (Eli Lilly And Co), as published by Dista Products Company, effective January 8, 2026 (SPL set c88f33ed-6dfb-4c5e-bc01-d8e36dd97299), via openFDA; the full label on DailyMed
What does the insulin glargine label say about fluoxetine?
Insulin glargine label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose reductions and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs.
Insulin Glargine label (Biocon Biologics Inc., January 23, 2026), drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Glargine-yfgn is coadministered with these drugs.
Source: FDA drug label (Insulin Glargine, BLA761201), Biocon Biologics Inc., effective January 23, 2026 (SPL set 3ac85ebb-5594-59c8-77fd-df254329d151), via openFDA
Source: FDA drug label (Toujeo, BLA206538), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set c9561d96-124d-48ca-982f-0aa1575bff36), via openFDA
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluoxetine | Insulin glargine | |
|---|---|---|
| Labeled for | Depression, Anxiety, Bipolar disorder | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0519 per capsule 40 mg capsule | $2.90 per mL 100 pen |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once